Olanzapine in the treatment of pathological gambling: A negative randomized placebo-controlled trial

Journal of Clinical Psychiatry

Volumn 69, Issue 3, 2008, Pages 433-440

  McElroy, Susan L ^a   Nelson, Erik B ^a   Welge, Jeffrey A ^a   Kaehler, Laura ^a   Keck Jr , Paul E ^a,b  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

OLANZAPINE; PLACEBO;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG WITHDRAWAL; EDEMA; FEEDING BEHAVIOR; FEMALE; HEADACHE; HUMAN; HYPOMANIA; INCREASED APPETITE; JOINT STIFFNESS; MALE; NERVOUSNESS; OUTCOME ASSESSMENT; OUTPATIENT; PARESTHESIA; PATHOLOGICAL GAMBLING; PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SEDATION; SIDE EFFECT; SOMNOLENCE; THINKING IMPAIRMENT; TREATMENT OUTCOME; XEROSTOMIA;

EID: 42249090206     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v69n0314     Document Type: Article

References (52)

1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision. Washington, DC: American Psychiatric Association; 2000
2. Shaffer HJ, Hall MN, Vander Bilt J. Estimating the prevalence of disordered gambling behavior in the United States and Canada: a research synthesis. Am J Public Health 1999;89:1369-1376
3. Grant JE, Potenza MN, eds. Pathological Gambling: A Clinical Guide to Treatment. Washington, DC: American Psychiatric Publishing; 2004
4. Grant JE, Williams KA, Kim SW. Update on pathological gambling. Curr Psychiatry Rep 2006;8:53-58
5. Pallanti S, Rossi NB, Hollander E. Pathological gambling. In: Hollander E, Stein DJ, eds. Clinical Manual of Impulse-Control Disorders. Washington, DC: American Psychiatric Publishing; 2006:251-289
6. Hollander E, Sood E, Pallanti S, et al. Pharmacological treatments of pathological gambling. J Gambl Stud 2005;21:99-108
7. Hollander E, Frenkel M, DeCaria C, et al. Treatment of pathological gambling with clomipramine [letter]. Am J Psychiatry 1992;149:710-711
8. Hollander E, DeCaria CM, Finkell JN, et al. A randomized double-blind fluvoxamine/placebo crossover trial in pathological gambling. Biol Psychiatry 2000;47:813-817
9. Blanco C, Petkova E, Ibanez A, et al. A pilot placebo-controlled study of fluvoxamine for pathological gambling. Ann Clin Psychiatry 2002;14:9-15
10. Kim SE, Grant JE, Adson DE, et al. A double-blind placebo-controlled study of the efficacy and safety of paroxetine in the treatment of pathological gambling. J Clin Psychiatry 2002;63:501-507
11. Saiz-Ruiz J, Blanco C, Ibáñez A, et al. Sertraline treatment of pathological gambling: a pilot study. J Clin Psychiatry 2005;66:28-33
12. Grant JE, Kim SW, Potenza MN, et al. Paroxetine treatment of pathological gambling: a multicenter randomized controlled trial. Int Clin Psychopharmacol 2003;18:243-249
13. Kim SW, Grant JE, Adson DE, et al. Double-blind naltrexone and placebo comparison study in the treatment of pathological gambling. Biol Psychiatry 2001;49:914-921
14. Grant JE, Potenza MN, Hollander E, et al. Multicenter investigation of the opioid antagonist nalmefene in the treatment of pathological gambling. Am J Psychiatry 2006;163:303-312
15. McElroy SL, Pope HG Jr, Keck PE Jr, et al. Are impulse-control disorders related to bipolar disorder? Compr Psychiatry 1996;37:229-240
16. Petry NM, Stinson FS, Grant BF. Comorbidity of DSM-IV pathological gambling and other psychiatric disorders: results from the National Epidemiologic Survey on Alcohol and Related Conditions. J Clin Psychiatry 2005;66:564-574
17. Hollander E, Pallanti S, Allen A, et al. Does sustained-release lithium reduce impulsive gambling and affective instability versus placebo in pathological gamblers with bipolar spectrum disorders? Am J Psychiatry 2005;162:137-145
18. Kim SW, Grant JE, Eckert ED, et al. Pathological gambling and mood disorders: clinical associations and treatment implications. J Affect Disord 2006;92:109-116
19. McIntyre RS, McElroy SL, Konarski JZ, et al. Problem gambling in bipolar disorder: results from the Canadian Community Health Survey [published online ahead of print Jan 19, 2007]. J Affect Disord 2007;102:27-34
20. Perlis RH, Welge JA, Vornik LA, et al. Atypical antipsychotics in the treatment of mania: a meta-analysis of randomized, placebo-controlled trials. J Clin Psychiatry 2006;67:509-516
21. Shelton RC. Olanzapine/fluoxetine combination for bipolar depression. Expert Rev Neurother 2006;6:33-39
22. Dando S, Tohen M. Olanzapine-relapse prevention following mania. J Psychopharmacol 2006;20(suppl 2):31-38
23. Haller R, Hinterhuber H. Treatment of pathological gambling with carbamazepine. Pharmacopsychiatry 1994;27:129
24. Pallanti S, Quercioli L, Sood E, et al. Lithium and valproate treatment of pathological gambling: a randomized single-blind study. J Clin Psychiatry 2002;63:559-564
25. Bymaster F, Perry KW, Nelson DL, et al. Olanzapine: a basic science update. Br J Psychiatry Suppl 1999;37:36-40
26. Bergh C, Eklund T, Soderstein P, et al. Altered dopamine function in pathological gambling. Psychol Med 1997;27:473-475
27. Goudriann AE, Oosterlaan J, de Beurs E, et al. Pathological gambling: a comprehensive review of biobehavioral findings. Neurosci Biobehav Rev 2004;28:123-141
28. Dodd ML, Klos KJ, Bower JH, et al. Pathological gambling caused by drugs used to treat Parkinson disease. Arch Neurol 2005;62:1377-1381
29. Weintraub D, Siderowf AD, Potenza MN, et al. Association of dopamine agonist use with impulse-control disorders in Parkinson disease. Arch Neurol 2006;63:969-973
30. Lesieur HR, Blume SB: The South Oaks Gambling Screen (SOGS): a new instrument for the identification of pathological gamblers. Am J Psychiatry 1987;144:1184-1188
31. Pallanti S, Decaria CM, Grant JE, et al. Reliability and validity of the Pathological Gambling Adaptation of the Yale-Brown Obsessive Compulsive Scale (PG-YBOCS). J Gambl Stud 2005;21:431-443
32. First MB, Spitzer RL, Gibbon M, et al. Structured Clinical Interview for DSM-IV-TR Axis I Disorders, Research Version, Patient Edition (SCID-I/P). New York, NY: Biometrics Research, New York State Psychiatric Institute; 2002
33. Guy W. ECDEU Assessment Manual for Psychopharmacology. US Dept Health, Education, and Welfare publication (ADM) 76-338; Rockville, Md: National Institute of Mental Health;1976:218-222
34. Hamilton M. Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol 1967;6:278-296
35. Young RC, Biggs JT, Ziegler VE, et al. A rating scale for mania: reliability, validity, and sensitivity. Br J Psychiatry 1978;133:429-435
36. Fitzmaurice GM, Laird NM, Ware JH. Applied Longitudinal Analysis. Hoboken, NJ: John Wiley & Sons; 2004
37. Gibbons RD, Hedeker D, Elkin I, et al. Some conceptual and statistical issues in analysis of longitudinal psychiatric data. Arch Gen Psychiatry 1993;50:739-750
38. Cohen J. Statistical Power Analysis for the Behavioral Sciences. 2nd ed. Hillsdale, NJ: Lawrence Erlbaum Associates; 1988
39. Spiegelhalter DJ, Abrams KR, Myles JP. Bayesian Approaches to Clinical Trials and Health-Care Evaluation. New York, NY: John Wiley & Sons; 2004
40. Grant JE, Potenza MN. Escitalopram treatment of pathological gambling with co-occurring anxiety: an open-label pilot study with double-blind discontinuation. Int Clin Psychopharmacol 2006;21:203-209
41. Ninan PT, McElroy SL, Kane CP, et al. Placebo-controlled study of fluvoxamine in the treatment of patients with compulsive buying. J Clin Psychopharmacol 2000;20:362-366
42. Koran LM, Chuong HW, Bullock KD, et al. Citalopram for compulsive shopping disorder: an open-label study followed by double-blind discontinuation. J Clin Psychiatry 2003;64:793-798
43. Hollander E, Tracy KA, Swann AC, et al. Divalproex in the treatment of impulsive aggression: efficacy in cluster B personality disorders. Neuropsychopharmacology 2003;28:1186-1197
44. Petry NM, Annerman Y, Bohl J, et al. Cognitive-behavioral therapy for pathological gamblers. J Consult Clin Psychol 2006;74:555-567
45. van Minnen A, Hoogduin KA, Keijers GP, et al. Treatment of trichotillomania with behavioral therapy or fluoxetine: a randomized, waiting-list controlled study. Arch Gen Psychiatry 2003;60:517-522
46. Hollander E, Stein DJ, eds. Clinical Manual of Impulse-Control Disorders. Washington, DC: American Psychiatric Publishing; 2006
47. Dell'Osso B, Allen A, Hollander E. Comorbidity issues in the pharmacological treatment of pathological gambling: a critical review. Clin Pract Epidemiol Ment Health 2005;1:21
48. Potenza MN, Chambers RA. Schizophrenia and pathological gambling [letter]. Am J Psychiatry 2001;158:497-498
49. Seedat S, Kesler S, Niehaus DJ, et al. Pathological gambling behavior: emergence secondary to treatment of Parkinson's disease with dopaminergic agents. Depress Anxiety 2000;11:185-186
50. Grant JE, Steinberg MA, Kim SW, et al. Preliminary validity and reliability testing of a Structured Clinical Interview for Pathological Gambling. Psychiatry Res 2004;128:79-88
51. Tolin DF, Abramowitz JS, Diefenbach GJ. Defining response in clinical trials for obsessive-compulsive disorder: a signal detection analysis of the Yale-Brown obsessive compulsive scale. J Clin Psychiatry 2005;66:1549-1557
52. Walker M, Toneatto T, Potenza MN, et al. A framework for reporting outcomes in problem gambling treatment research: the Banff, Alberta Consensus. Addiction 2006;101:504-511